Do you want to read an article? Please log in or register.
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Related content
Lung Cancer
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study
Lung Cancer
Supiot R, Gherardi A, du Manoir de Juaye L, Doghri O, Sivignon M, Duruisseaux M, Chouaid C
doi: 10.1016/j.lungcan.2025.108885
Lung Cancer
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial
Lancet Respir Med
Gerber DE, Wang Y, Langer CJ, Khullar OV, Kozono DE, Cornelius LA, Forde PM, Nwaneri MO, Neal JW, Talsania A, Leal TA, Patel M, Donthireddy KR, Waqar SN, Chaft JE, Govindan R, Sands JM, Malik S, Li T, Sun Z, Stinchcombe TE, Vokes EE, Mandrekar SJ, Oxnard GR, Carbone DP, Ramalingam SS
doi: 10.1016/S2213-2600(26)00192-X
Lung Cancer
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)
Clin Lung Cancer
Mitome N, Hamada A, Wakabayashi M, Uozumi T, Horinouchi H, Isaka M, Yotsukura M, Aokage K, Fukuda H, Watanabe SI, Tsutani Y, Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG)
doi: 10.1016/j.cllc.2026.04.006
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
Lung Cancer
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
ESMO Open
Frehner L, Schär S, Hayoz S, Guckenberger M, Finazzi T, Mark M, Addeo A, Mauti LA, Betticher D, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D, Opitz I, Ris HB, Özdemir BC, Schmid S
doi: 10.1016/j.esmoop.2025.105870
COMMENTED
Lung Cancer
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Ann Oncol
Wakelee H, Spicer JD, Gao S, Liberman M, Tsuboi M, Kato T, Chen KN, Dooms C, Majem M, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Halmos B, Jones DR, Chaft JE, Reck M, Jensen E, Keller SM, Samkari A, Garassino MC
doi: 10.1016/j.annonc.2026.08.005
Lung Cancer
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer
Nat Commun
Zhou F, Su C, Liang W, Xu LD, Tao W, Qian J, Xu S, Liu D, Fan R, Zhang Y, Liu Y, Wu L, Fu X, Zhang X, Shen N, Ge D, Chen Q, Mao W, Xu L, Chen C, Hu B, Shao G, Hu J, Zhao J, Liu X, Liu Z, Wang Z, Xiao Z, Gong T, Lin W, Li X, Ye F, Liu Y, Ma H, Huang Y, Zhou J, Wang Z, Fu J, Ding L, Mao L, Chen W, He J, Zhou C
doi: 10.1038/s41467-026-76392-9
RECOMMENDED
Lung Cancer
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Dingemans AC, Opitz I, Brunelli A, Remon J, Hendriks LEL, Edwards J, Faivre-Finn C, Reguart N, Smit EF, Levy A, Sanchez-Lorente D, Trujillo JC, Filippi AR, Stathopoulos K, Blum TG, Guckenberger M, Popat S, De Angelis R, Hofman P, von der Thüsen J, Hartemink KJ, Petersen RH, Ruffini E, Dickhoff C, Houda I, Prisciandaro E, De Ruysscher D, Derks J, Bahce I, Mariolo A, Besse B, Xenophontos E, Giaj Levra N, van Schil P, Brandão M, Berghmans T
doi: 10.1016/S2213-2600(26)00051-2
RECOMMENDED
Lung Cancer
Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Mountzios G, Weng JK, Zairi E, Hsieh K, Chander P, Dunlop W, Qiao Y, Wang A, Januszewski A
doi: 10.1016/j.cllc.2026.01.005